SCHEMBL676509

SCHEMBL676509

CSc1c2c(=O)n(C)c(=O)n(CC(C)(C)C)c2nn1Cc1ccc(-n2cncn2)cc1

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 2/20 0.39
CYP11B2 P19099 1/20 0.35
KDM4E B2RXH2 2/20 0.34
ABCC8 Q09428 1/20 0.32
KCNJ11 Q14654 1/20 0.32
PDE1B Q01064 3/20 0.32
PDE2A O00408 1/20 0.32
PDE4D Q08499 1/20 0.32
DPP8 Q6V1X1 1/20 0.32
BRS3 P32247 1/20 0.31
PDE1A P54750 1/20 0.31
PDE1C Q14123 1/20 0.31
GRM2 Q14416 2/20 0.31
ALDH1A1 P00352 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
TPH1 P17752 2/20 0.30
TPH2 Q8IWU9 2/20 0.30
PPARD Q03181 2/20 0.30
PPARA Q07869 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL676325 0.89 DPP4 (0.37) DPP4CYP11B2PDE1BPDE2APDE1A
SCHEMBL675773 0.86 USP1 (0.42) DPP4PDE1BPDE2APDE4D
SCHEMBL674792 0.85 DPP4 (0.38) DPP4CYP11B2KDM4EABCC8KCNJ11
SCHEMBL675988 0.84 DPP4 (0.38) DPP4CYP11B2ABCC8KCNJ11PDE1B
SCHEMBL2120812 0.82 PDE1B (0.50) DPP4CYP11B2PDE1BPDE2APDE4D
SCHEMBL675577 0.81 GRM2 (0.42) GRM2ALDH1A1PPARA
SCHEMBL676897 0.81 MAOB (0.38) ABCC8KCNJ11PDE1BPDE2APDE4D
SCHEMBL678944 0.81 PDE1B (0.36) ABCC8KCNJ11PDE1BPDE2APDE4D
SCHEMBL676380 0.81 PDE1B (0.49) PDE1BPDE2APDE4DPDE1APDE1C
SCHEMBL680616 0.79 PDE1B (0.44) PDE1BPDE2APDE4DPDE1APDE1C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9487527-B2 Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione derivatives useful as inhibitors of phosphodiesterase I INTRA-CELLULAR THERAPIES, INC. (US) 2016-11-08 US disclosed
US-20150119370-A1 Organic Compounds LI PENG (US) 2015-04-30 US disclosed
US-8859564-B2 Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione derivatives useful as inhibitors of phosphodiesterase 1 INTRA-CELLULAR THERAPIES, INC. (US) 2014-10-14 US disclosed
US-8859564-B2 Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione derivatives useful as inhibitors of phosphodiesterase 1 INTRA-CELLULAR THERAPIES, INC. (US) 2014-10-14 US disclosed
US-8859564-B2 Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione derivatives useful as inhibitors of phosphodiesterase 1 INTRA-CELLULAR THERAPIES, INC. (US) 2014-10-14 US disclosed
EP-2367430-B1 ORGANIC COMPOUNDS INTRA CELLULAR THERAPIES INC (US) 2014-08-13 EP disclosed
EP-2367430-B1 ORGANIC COMPOUNDS INTRA CELLULAR THERAPIES INC (US) 2014-08-13 EP disclosed
US-20110281832-A1 ORGANIC COMPOUNDS INTRA-CELLULAR THERAPIES, INC. 2011-11-17 US disclosed
US-20110281832-A1 ORGANIC COMPOUNDS INTRA-CELLULAR THERAPIES, INC. 2011-11-17 US disclosed
US-20110281832-A1 ORGANIC COMPOUNDS INTRA-CELLULAR THERAPIES, INC. 2011-11-17 US disclosed
WO-2010065152-A1 ORGANIC COMPOUNDS INTRA-CELLULAR THERAPIES, INC. (US) 2010-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110281832-A1 ORGANIC COMPOUNDS CYP2C9, CYP2C19, CYP3A4 DPP4 99/4885CYP11B2 66/4885KDM4E 1748/4885
US-20150119370-A1 Organic Compounds CYP2C19, CYP2C9, CYP3A43 DPP4 1117/4885CYP11B2 27/4885KDM4E 3144/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.